Badanie ONTARGET z perspektywy czasu. Czy jest jeszcze miejsce dla podwójnej blokady osi renina-angiotensyna-aldosteron? Komentarz
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
cze 30, 2009
##plugins.themes.bootstrap3.article.main##
Abstrakt
Brak
##plugins.themes.bootstrap3.article.details##
Jak cytować
Kuch , M. (2009). Badanie ONTARGET z perspektywy czasu. Czy jest jeszcze miejsce dla podwójnej blokady osi renina-angiotensyna-aldosteron?. Medycyna Faktów , 2(2(3), 45-49. Pobrano z https://journalsmededu.pl/index.php/jebm/article/view/2665
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Pfeffer M.A., McMurray J.J.V., Velazquez E.J. et al.: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N. Engl. J. Med. 2003; 349: 1893-906 [Erratum: N. Engl. J. Med. 2004; 350: 203].
2. Pfeffer M.A., Swedberg K., Grenger C.B. et al.: Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362: 759-766.
3. Cohn J.N., Tognoni G.A.: Randomized trial of the angiotensin receptor blocker valsartan in chronic heart failure. N. Engl. J. Med. 2001; 345: 1667-1675.
4. Fox K., Garcia M.A.A., Ardissino D. et al.: Guidelines on the management of stable angina pectoris: executive summary. The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. European Heart Journal 2006; 27: 1341-1381.
5. Dickstein K., Cohen-Solan A., Filippatos G. et al.: ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of ESC and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur. Heart J. 2008; 29: 2388-2442.
6. Menard J., Cambell D.J., Azizi M., Gonzales M.F.: Synergic effects of ACE inhibition and Ang II antagonism on blood pressure, cardiac weight, and renin in spontaneously hypertensive rats. Circulation 1997; 96: 3072-8.
7. McKelvie R.S., Yusuf S., Pericak D.: Comparison of Candesartan, Enalapril, and Their Combination in Congestive Heart Failure. Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVED) Pilot Study: The RESOLVED Pilot Study Investigators. Circulation 1999; 100: 1056-1064.
8. McMurray J.J., Ostergren J., Swedberg K. et al.: Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function taking angiotensin-converting enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362: 767-71.
9. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. N. Engl. J. Med. 2000; 342: 145-53.
10. The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET) Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. 2008; 358: 1547-59.
11. Kunz R., Friedrich C., Wolbers M., Mann J.F.: Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann. Intern. Med. 2008; 148: 30-48.
12. Nakao N., Yoshimura A., Morita H. et al.: Combination treatment of angiotensin-II receptor and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomized controlled trial. Lancet 2003; 361: 117-124.
13. Mann J.F.E., Schmieder R.E., McQueen M. et al. (on behalf of the ONTARGET Investigators): Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomized, double-blind, controlled trial. Lancet 2008; 372: 547-53.
14. Phillips C.O., Kashani A., Ko D.K. et al.: Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials. Arch. Intern. Med. 2007; 167: 1930-36.
15. The Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators; Yusuf S., Teo K., Anderson C. et al.: Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomized controlled trial. Lancet 2008; 372: 1174-83.
16. The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators: Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-88.
17. The Prevention of Events with Angiotensin Converting Enzyme Inhibition (PEACE) Investigators: Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N. Engl. J. Med. 2004; 351: 2058-68.
18. Yusuf S., Diener H.C., Sacco R.L. et al. (PRoFESS Study Group): Telmisartan to prevent recurrent stroke and cardiovascular events. N. Engl. J. Med. 2008; 359: 1225-37.
19. Granger C.B., McMurray J.J.V., Yusuf S. et al. (for the CHARM Investigators and Committees): Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003; 362: 772-76.
20. Mancia G., De Backer G., Dominiczak A. et al.: 2007 Guidelines for the Management of Arterial Hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur. Heart J. 2007; 28: 1462-1536.
21. Task Force for Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of European Society of Cardiology, Bassand J.P., Hamm C.W., Ardissino D. et al.: Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur. Heart J. 2007; 28: 1598-660.34
2. Pfeffer M.A., Swedberg K., Grenger C.B. et al.: Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362: 759-766.
3. Cohn J.N., Tognoni G.A.: Randomized trial of the angiotensin receptor blocker valsartan in chronic heart failure. N. Engl. J. Med. 2001; 345: 1667-1675.
4. Fox K., Garcia M.A.A., Ardissino D. et al.: Guidelines on the management of stable angina pectoris: executive summary. The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. European Heart Journal 2006; 27: 1341-1381.
5. Dickstein K., Cohen-Solan A., Filippatos G. et al.: ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of ESC and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur. Heart J. 2008; 29: 2388-2442.
6. Menard J., Cambell D.J., Azizi M., Gonzales M.F.: Synergic effects of ACE inhibition and Ang II antagonism on blood pressure, cardiac weight, and renin in spontaneously hypertensive rats. Circulation 1997; 96: 3072-8.
7. McKelvie R.S., Yusuf S., Pericak D.: Comparison of Candesartan, Enalapril, and Their Combination in Congestive Heart Failure. Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVED) Pilot Study: The RESOLVED Pilot Study Investigators. Circulation 1999; 100: 1056-1064.
8. McMurray J.J., Ostergren J., Swedberg K. et al.: Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function taking angiotensin-converting enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362: 767-71.
9. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. N. Engl. J. Med. 2000; 342: 145-53.
10. The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET) Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. 2008; 358: 1547-59.
11. Kunz R., Friedrich C., Wolbers M., Mann J.F.: Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann. Intern. Med. 2008; 148: 30-48.
12. Nakao N., Yoshimura A., Morita H. et al.: Combination treatment of angiotensin-II receptor and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomized controlled trial. Lancet 2003; 361: 117-124.
13. Mann J.F.E., Schmieder R.E., McQueen M. et al. (on behalf of the ONTARGET Investigators): Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomized, double-blind, controlled trial. Lancet 2008; 372: 547-53.
14. Phillips C.O., Kashani A., Ko D.K. et al.: Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials. Arch. Intern. Med. 2007; 167: 1930-36.
15. The Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators; Yusuf S., Teo K., Anderson C. et al.: Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomized controlled trial. Lancet 2008; 372: 1174-83.
16. The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators: Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-88.
17. The Prevention of Events with Angiotensin Converting Enzyme Inhibition (PEACE) Investigators: Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N. Engl. J. Med. 2004; 351: 2058-68.
18. Yusuf S., Diener H.C., Sacco R.L. et al. (PRoFESS Study Group): Telmisartan to prevent recurrent stroke and cardiovascular events. N. Engl. J. Med. 2008; 359: 1225-37.
19. Granger C.B., McMurray J.J.V., Yusuf S. et al. (for the CHARM Investigators and Committees): Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003; 362: 772-76.
20. Mancia G., De Backer G., Dominiczak A. et al.: 2007 Guidelines for the Management of Arterial Hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur. Heart J. 2007; 28: 1462-1536.
21. Task Force for Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of European Society of Cardiology, Bassand J.P., Hamm C.W., Ardissino D. et al.: Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur. Heart J. 2007; 28: 1598-660.34